The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan

[1]  J. Herndon,et al.  Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. , 2004, Lung cancer.

[2]  P C Goodman,et al.  Staging non-small cell lung cancer with whole-body PET. , 1999, Radiology.

[3]  O Munck,et al.  What do early bone scans tell about breast cancer patients? , 1982, European journal of cancer & clinical oncology.

[4]  M. Perry,et al.  Bone marrow involvement in small cell lung cancer. Clinical significance and correlation with routine laboratory variables , 1989, Cancer.

[5]  V. Combaret,et al.  Bone marrow metastases in small cell lung cancer: detection with magnetic resonance imaging and monoclonal antibodies. , 1989, British Journal of Cancer.

[6]  Eyal Mishani,et al.  Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  E. Mittra,et al.  Novel Strategy for a Cocktail 18F-Fluoride and 18F-FDG PET/CT Scan for Evaluation of Malignancy: Results of the Pilot-Phase Study , 2009, Journal of Nuclear Medicine.

[8]  G. Blake,et al.  Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. , 2001, Seminars in nuclear medicine.

[9]  D. Vanel,et al.  MRI of bone marrow disorders , 2000, European Radiology.

[10]  O. Schober,et al.  FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy , 2000, European Journal of Nuclear Medicine.

[11]  Naoto T Ueno,et al.  Bone imaging in metastatic breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  T. Powles,et al.  DETECTION OF BREAST CARCINOMA METASTASES IN BONE: RELATIVE MERITS OF X-RAYS AND SKELETAL SCINTIGRAPHY , 1983, The Lancet.

[13]  N. Erdal,et al.  Bone Marrow Involvement in Small Cell Lung Cancer , 2004 .

[14]  W A Murphy,et al.  Bone marrow imaging. , 1988, Radiology.

[15]  H. Groen,et al.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.

[16]  I. Fogelman,et al.  The role of positron emission tomography in the management of bone metastases , 2000, Cancer.

[17]  L. Rybak,et al.  Radiological imaging for the diagnosis of bone metastases. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[18]  T. Turkington,et al.  Clinical applications of PET in oncology. , 2004, Radiology.

[19]  Tamer Özülker,et al.  Comparison of 18F-FDG-PET/CT with 99mTc-MDP bone scintigraphy for the detection of bone metastases in cancer patients , 2010, Nuclear medicine communications.

[20]  E. Bombardieri,et al.  Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[21]  G. F. Gates,et al.  SPECT bone scanning of the spine. , 1998, Seminars in nuclear medicine.

[22]  P. Rigo,et al.  Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer , 1998, European Journal of Nuclear Medicine.

[23]  J. Aerts,et al.  18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers , 2008, Nuclear medicine communications.

[24]  S. Baba,et al.  Comparison of18FDG-PET with99mTc-HMDP scntigraphy for the detection of bone metastases in patients with breast cancer , 2005, Annals of nuclear medicine.

[25]  Adilson Prando,et al.  Baseline staging of newly diagnosed prostate cancer: a summary of the literature. , 2004, International braz j urol : official journal of the Brazilian Society of Urology.

[26]  G. Sze,et al.  Current imaging in spinal metastatic disease. , 1991, Seminars in oncology.

[27]  H. Schirrmeister,et al.  Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  U. Metser,et al.  The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  J. Pruim,et al.  DETECTION OF BONE METASTASES IN PROSTATE CANCER BY 18-F SODIUM FLUORIDE PET , 2006 .

[30]  M. Endo,et al.  Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. , 2005, AJR. American journal of roentgenology.

[31]  Hans-Jürgen Gallowitsch,et al.  F-18 Fluorodeoxyglucose Positron-Emission Tomography in the Diagnosis of Tumor Recurrence and Metastases in the Follow-Up of Patients With Breast Carcinoma: A Comparison to Conventional Imaging , 2003, Investigative radiology.

[32]  Christian Schumann,et al.  Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  W. Bezwoda,et al.  Bone marrow involvement in anaplastic small cell lung cancer: Diagnosis, hematologic features, and prognostic implications , 1986, Cancer.

[34]  T. Powles,et al.  The role of computed tomography in the detection of bone metastases in breast cancer patients. , 1983, The British journal of radiology.

[35]  H. Schirrmeister,et al.  Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Wahl,et al.  Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. , 1996, Radiology.

[37]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[38]  J. Buckwalter,et al.  Metastatic disease of the skeleton. , 1997, American family physician.

[39]  J Kotzerke,et al.  Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  Kuwabara,et al.  Comparison of 18 FDG-PET with 99 mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer , 2005 .

[41]  I. Kunkler,et al.  The value of non-staging skeletal scintigraphy in breast cancer. , 1986, Clinical radiology.

[42]  N. Lee,et al.  Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. , 2000, International journal of radiation oncology, biology, physics.

[43]  Yen-Wen Wu,et al.  The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients , 2010, Nuclear medicine communications.